Today

Nasdaq filed Form 25 to remove GigCapital7 units (GIGGU) from Nasdaq.

Regulation A amendment cuts the offering price to $0.008 per share.

Company filed a registered direct offering with shares, pre-funded warrants and placement-agent warrants.

Embrace Change filed a Form 12b-25 notifying a late 10-Q and outstanding 2025 10-K.

Kanzhun's 6‑K (with Exhibit 99.1) discloses bulk issuance of 647,636 Class A ordinary shares to the ADS depositary reserved for ADS issuance and settlement/vesting of 20,000 RSUs on May 26, 2026 — potential dilution exists but materiality is unclear without market context.

Six-K includes Exhibit 99.1 with 12-month earnings and coverage metrics (e.g., $13,030 million earnings before interest on subordinated indebtedness and income tax; $674 million adjusted amount; subordinated interest requirements $326 million; grossed-up dividend coverage ~62%).

G-III Apparel Group declared a quarterly cash dividend of $0.10 per share, payable July 8, 2026 to holders of record on June 22, 2026 (Exhibit 99.1). Market context (price / shares outstanding) is needed to compute yield and aggregate payout.

Movado reported improving first-quarter fiscal 2027 results (net sales ~$142.4M; operating income $7.0M; diluted EPS $0.30) and the Board approved a quarterly dividend and share repurchase program. Positive operating leverage and margin expansion appear to have driven the EPS recovery; market context and exact capital-return sizing are needed to assess investor impact.

Precision BioSciences reported late-breaker Phase 1 ELIMINATE-B data at EASL claiming a 1-log reduction in cccDNA-derived transcripts and pgRNA loss in all patients with detectable pgRNA (n=6). Results are promising but early and based on small cohorts — further review and market context needed.

Bank of Nova Scotia filed a Form 6-K with exhibits (99.1, 99.2) that include a consolidated capitalization table as at April 30, 2026 (subordinated debentures 5,766; common shares 22,002; retained earnings 59,876; total common equity 77,222; preferred shares and other equity instruments 9,939). The filing notes IFRS 17 adoption; full income/stated-period earnings metrics are not extracted in the wrapper — analyst review recommended.

Monro (MNRO) announced a formal review of strategic alternatives (Exhibit 99.2), furnished Q4/FY26 results (Exhibit 99.1) showing reduced sales and a $6.6M net loss for the quarter, and the board declared a $0.28 quarterly dividend payable June 16, 2026. The strategic review could lead to significant corporate actions; details and market context are needed to assess materiality.

Fusion Fuel (HTOO) filed a 6‑K announcing an EGM on June 8, 2026 to approve the Royal Uranium acquisition, conversion of 4,171,327 preferred shares into ordinary shares, and a proposed name change; the board recommends voting FOR. Key transaction economics and pro‑forma share counts are not provided in the filing.

Davis Commodities filed a Form 6‑K furnishing a press release (Exhibit 99.1) clarifying recent reports about a May 14, 2026 Singapore High Court order in a dispute between Raízen Trading SA and Carfax Commodities (Asia) Pte. The filing does not disclose whether Davis is directly named or quantify any exposure; more detail is needed to assess investor impact.

FDA accepted Grace's NDA for GTx-104 and set an April 23, 2026 PDUFA date.

Nano Dimension announced sale of MarkForged to Stratasys in an all-cash transaction (reported ~ $42M) and expects to reduce annualized cash burn by approximately $15M; transaction should improve near-term liquidity but market impact depends on company cash, revenue contribution of MarkForged, and timing/receipt of proceeds.

Stratasys furnished a press release (Exhibit 99.1) titled 'Agreement for Acquisition of Markforged, Inc.' The exhibit references an all-cash transaction (~$42.5M) and notes Markforged generated ~$70M in 2025; the 6-K is a short wrapper and the exhibit needs analyst review to confirm parties, payment mechanics, closing conditions and expected financial impact on Stratasys.

Positive Phase 2 Part B readout: mid-dose zumilokibart showed substantially higher EASI-75 and IGA responses vs placebo at Week 16 with mid-dose selected as planned Phase 3 dose and acceptable conjunctivitis rates versus higher doses.

Apogee entered a revenue participation sale with BXLS for $100M upfront (May 26, 2026) with additional tranche options and tiered revenue-share percentages; company removed cash‑runway guidance. This materially improves near‑term liquidity but creates long‑term revenue share obligations that could reduce future net product receipts if zumilokibart achieves high sales.

TSMC's board approved distribution of NT$155,595,147,126 (NT$6.00 per share) for 4Q2025, payable July 9, 2026. The filing provides amount, per-share figure, and payment date but lacks market-context (shares outstanding, price, FX) needed to assess yield and materiality.

Capri issued Q4/FY2026 results (Exhibit 99.1): total revenue of $796M (down ~3%), net debt improved to $222M from $1.4B, cash $135M, recorded a $65M IEEPA tariff refund receivable, and announced repurchase activity (text-truncated in filing). Company provided FY2027 low-single-digit revenue guidance and 40% adjusted EPS growth but did not provide a GAAP reconciliation for the non-GAAP outlook.